{"title":"类风湿关节炎患者MTRR 66 A/G和MTR 2756 A/G多态性与甲氨蝶呤应答的关系一个荟萃分析。","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1097/RHU.0000000000002257","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>This study aimed to investigate the association between methotrexate (MTX) response in rheumatoid arthritis and the polymorphisms methionine synthase reductase (MTRR) 66 A/G and methionine synthase (MTR) 2756 A/G. Relevant studies were identified through searches in MEDLINE, EMBASE, Web of Science, and Cochrane databases. A meta-analysis was conducted to evaluate the relationship between MTX response and the MTRR 66 A/G and MTR 2756 A/G polymorphisms. Eight studies that examined MTRR 66 A/G (with 688 responders and 541 nonresponders) and MTR 2756 A/G (518 responders and 261 nonresponders) were included. The meta-analysis found no significant association between MTX responsiveness and the MTRR 66 GG + GA genotype (odds ratio [OR] = 1.289, 95% confidence interval [CI] = 0.991-1.676, p = 0.059). However, stratified analysis revealed a significant association in studies with larger sample sizes (n ≥ 150) (OR = 1.343, 95% CI = 1.015-1.776, p = 0.039), but not in smaller studies (n < 150) (OR = 0.952, 95% CI = 0.444-2.039, p = 0.899). No association was found with treatment response based on follow-up duration. The MTR 2756 GG + GA genotype also showed no significant association with MTX responsiveness (OR = 1.053, 95% CI = 0.765-1.450, p = 0.751). Subgroup analyses by ethnicity, sample size, and follow-up period revealed no additional associations with treatment response. The limited number of studies (n = 4) for the MTR 2756 A/G polymorphism was included in the meta-analysis for the MTR 2756 A/G polymorphism, which has the potential for reduced statistical power as a consequence. This meta-analysis suggests that the MTRR 66 A/G GG + GA genotype is associated with a better response to MTX treatment in rheumatoid arthritis, whereas the MTR 2756 A/G polymorphism does not significantly impact treatment response. However, the significant association between MTRR 66 A/G and MTX response was observed only in the subgroup of larger studies, which indicates that the overall strength of evidence might be weak.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association Between MTRR 66 A/G and MTR 2756 A/G Polymorphisms and Response to Methotrexate in Rheumatoid Arthritis. A Meta-analysis.\",\"authors\":\"Young Ho Lee, Gwan Gyu Song\",\"doi\":\"10.1097/RHU.0000000000002257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>This study aimed to investigate the association between methotrexate (MTX) response in rheumatoid arthritis and the polymorphisms methionine synthase reductase (MTRR) 66 A/G and methionine synthase (MTR) 2756 A/G. Relevant studies were identified through searches in MEDLINE, EMBASE, Web of Science, and Cochrane databases. A meta-analysis was conducted to evaluate the relationship between MTX response and the MTRR 66 A/G and MTR 2756 A/G polymorphisms. Eight studies that examined MTRR 66 A/G (with 688 responders and 541 nonresponders) and MTR 2756 A/G (518 responders and 261 nonresponders) were included. The meta-analysis found no significant association between MTX responsiveness and the MTRR 66 GG + GA genotype (odds ratio [OR] = 1.289, 95% confidence interval [CI] = 0.991-1.676, p = 0.059). However, stratified analysis revealed a significant association in studies with larger sample sizes (n ≥ 150) (OR = 1.343, 95% CI = 1.015-1.776, p = 0.039), but not in smaller studies (n < 150) (OR = 0.952, 95% CI = 0.444-2.039, p = 0.899). No association was found with treatment response based on follow-up duration. The MTR 2756 GG + GA genotype also showed no significant association with MTX responsiveness (OR = 1.053, 95% CI = 0.765-1.450, p = 0.751). Subgroup analyses by ethnicity, sample size, and follow-up period revealed no additional associations with treatment response. The limited number of studies (n = 4) for the MTR 2756 A/G polymorphism was included in the meta-analysis for the MTR 2756 A/G polymorphism, which has the potential for reduced statistical power as a consequence. This meta-analysis suggests that the MTRR 66 A/G GG + GA genotype is associated with a better response to MTX treatment in rheumatoid arthritis, whereas the MTR 2756 A/G polymorphism does not significantly impact treatment response. However, the significant association between MTRR 66 A/G and MTX response was observed only in the subgroup of larger studies, which indicates that the overall strength of evidence might be weak.</p>\",\"PeriodicalId\":520664,\"journal\":{\"name\":\"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/RHU.0000000000002257\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/RHU.0000000000002257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
摘要:本研究旨在探讨甲氨蝶呤(MTX)在类风湿关节炎中的反应与蛋氨酸合成酶还原酶(MTRR) 66 A/G和蛋氨酸合成酶(MTR) 2756 A/G多态性之间的关系。相关研究通过MEDLINE、EMBASE、Web of Science和Cochrane数据库进行检索。荟萃分析评估了MTX反应与MTRR 66 A/G和MTR 2756 A/G多态性之间的关系。纳入了8项研究,检查了MTRR 66 A/G(688名应答者和541名无应答者)和MTR 2756 A/G(518名应答者和261名无应答者)。meta分析发现MTX反应性与MTRR 66 GG + GA基因型之间无显著相关性(优势比[OR] = 1.289, 95%可信区间[CI] = 0.991-1.676, p = 0.059)。然而,分层分析显示,在样本量较大(n≥150)的研究中(OR = 1.343, 95% CI = 1.015-1.776, p = 0.039),而在样本量较小的研究中(n < 150)则无显著相关性(OR = 0.952, 95% CI = 0.444-2.039, p = 0.899)。没有发现与基于随访时间的治疗反应相关。MTR 2756 GG + GA基因型也与MTX反应性无显著相关性(OR = 1.053, 95% CI = 0.765-1.450, p = 0.751)。按种族、样本量和随访期进行的亚组分析显示,与治疗反应没有额外的关联。MTR 2756 A/G多态性的有限数量的研究(n = 4)被纳入MTR 2756 A/G多态性的荟萃分析,这可能会因此降低统计效力。这项荟萃分析表明,MTRR 66 A/G GG + GA基因型与类风湿性关节炎患者对MTX治疗的更好反应相关,而MTR 2756 A/G多态性对治疗反应没有显著影响。然而,MTRR 66 A/G与MTX反应之间的显著关联仅在大型研究的亚组中观察到,这表明证据的总体强度可能较弱。
Association Between MTRR 66 A/G and MTR 2756 A/G Polymorphisms and Response to Methotrexate in Rheumatoid Arthritis. A Meta-analysis.
Abstract: This study aimed to investigate the association between methotrexate (MTX) response in rheumatoid arthritis and the polymorphisms methionine synthase reductase (MTRR) 66 A/G and methionine synthase (MTR) 2756 A/G. Relevant studies were identified through searches in MEDLINE, EMBASE, Web of Science, and Cochrane databases. A meta-analysis was conducted to evaluate the relationship between MTX response and the MTRR 66 A/G and MTR 2756 A/G polymorphisms. Eight studies that examined MTRR 66 A/G (with 688 responders and 541 nonresponders) and MTR 2756 A/G (518 responders and 261 nonresponders) were included. The meta-analysis found no significant association between MTX responsiveness and the MTRR 66 GG + GA genotype (odds ratio [OR] = 1.289, 95% confidence interval [CI] = 0.991-1.676, p = 0.059). However, stratified analysis revealed a significant association in studies with larger sample sizes (n ≥ 150) (OR = 1.343, 95% CI = 1.015-1.776, p = 0.039), but not in smaller studies (n < 150) (OR = 0.952, 95% CI = 0.444-2.039, p = 0.899). No association was found with treatment response based on follow-up duration. The MTR 2756 GG + GA genotype also showed no significant association with MTX responsiveness (OR = 1.053, 95% CI = 0.765-1.450, p = 0.751). Subgroup analyses by ethnicity, sample size, and follow-up period revealed no additional associations with treatment response. The limited number of studies (n = 4) for the MTR 2756 A/G polymorphism was included in the meta-analysis for the MTR 2756 A/G polymorphism, which has the potential for reduced statistical power as a consequence. This meta-analysis suggests that the MTRR 66 A/G GG + GA genotype is associated with a better response to MTX treatment in rheumatoid arthritis, whereas the MTR 2756 A/G polymorphism does not significantly impact treatment response. However, the significant association between MTRR 66 A/G and MTX response was observed only in the subgroup of larger studies, which indicates that the overall strength of evidence might be weak.